Can margins hold? Q2 test after customs-duty hit
Manorama's Q1 momentum — 39.5% revenue growth, 67.5% profit jump — set a high bar. Q2 must prove the specialty-fats surge wasn't a blip, and margins can stay robust after August's ₹20.64 Cr customs outflow.
The setup: Manorama shattered the ₹400 Cr quarterly ceiling in Q1 FY27 — revenue ₹404.0 Cr, up 39.5% YoY, and consolidated PAT leapt 67.5% to ₹78.7 Cr. The stock rallied 8% on the news, and the Street's median target (₹2,003) sits 25.9% above the current ₹1,957.8 (as of Nov 6). But Q2 is the real test: can the company hold margins after a ₹20.64 Cr customs duty hit in August, and does the specialty-fats boom stick as demand normalizes?
~₹390 Cr
On-plan pace; Q1 ₹404 Cr sets high bar; seasonal Q2 softness typical in edible oils
25–27%
Company guidance; Q1 ran at 26.8%; watch for commodity cost pass-through
~₹65–75 Cr
Q1 consolidated PAT ₹78.7 Cr; normalize for seasonal mix & no outsized items
₹1,670 Cr revenue
+22.1% YoY; implies Q3–Q4 slower than H1; reaffirmation critical
What strong vs weak looks like: STRONG: Q2 revenue ₹400+ Cr (holds the ₹400 Cr run-rate; specialty-fats demand intact); EBITDA margin 26%+ (shows cost control despite customs hit); cash flow robust; any guidance uplift for FY27; West Africa expansion tracking. Market re-rates on execution confidence. WEAK: Q2 revenue <₹370 Cr (reversal to pre-Q1 trends; volume rollover or pricing pressure); EBITDA margin <25% (margin compression post-duty; input costs bite harder); FY27 guidance lowered or flat; West Africa capex drag shows up. Stock sentiment swings to "growth was one-quarter wonder."
On track? Manorama committed to FY27 revenue growth of +22.1% YoY (₹1,670 Cr). H1 implies ~₹800 Cr run (Q1 ₹404 + Q2 ~₹390), which puts them on track for a ₹1,670 Cr full year — assuming Q3–Q4 compounds at a steady pace. The real question is margin: Q1's 26.8% EBITDA margin is above the 25–27% guided range. If Q2 holds 25%+, the company has proven the customs hit was a one-time cash drain, not an operational reset. If margins slip <25%, Street consensus (which prices 27% EBITDA margin into targets) will reset lower.
1 · Margin hold post-customs
Did the ₹20.64 Cr duty payment (Aug) leave a lasting scar? Watch EBITDA margin: if Q2 is 25%+, the hit was cash-only (already absorbed); if <25%, input-cost pressure or input-mix erosion is real. This is the margin call for FY27 guidance credibility.
2 · Seasonality & volumes
Q2 typically softer than Q1 in edible oils (post-harvest, inventory normalization). Q2 <₹370 Cr would signal either volume rollover (demand weakness) or pricing pullback (commodity pressure). Q2 ≥₹390 Cr keeps the growth narrative alive. Revenue commentary will matter as much as the number.
3 · FY27 guide reaffirmation
Will the company reaffirm ₹1,670 Cr FY27 revenue (or adjust)? If they upgrade, Street will re-rate. If they downgrade or narrow range, expect selling on the release (Q1 was the peak; Q3–Q4 slower). Management tone on specialty-fats demand and West Africa capex spend will signal confidence or caution.
Since last quarter: filings scan
Aug 10, 2026
Customs duty settlement: ₹20.64 Cr paid (differential duty, IGST, penalty on imported Palm Mid Fraction eligibility dispute)
Cash headwind absorbed; likely behind them. No ongoing regulatory risk disclosed.
Aug 11, 2026
BSE clarification on customs inquiry disclosure delay
Routine compliance filing; no new operational risk.
Sep 4, 2026
Board approves Dr. Rohini Tiwari as Independent Director; director appointment & subsidiary capex increases approved
Routine governance. Subsidiary capex increases signal West Africa expansion capex continues (as guided).
Sep 22, 2026
Board approves share capital increase for three wholly-owned subsidiaries (Benin, Chad, Burkina Faso)
West Africa expansion on track. Capex allocation tracking to guidance.
Sep 26, 2026
Trading window closes for Q2 FY27 results
Routine; signals board confidence ahead of earnings.
Aug 27, 2026
FY26 Annual Report filed; AGM scheduled Sep 21, 2026
Routine annual governance; no new disclosures on FY27 guidance.
Nov 4, 2026
Board meeting intimation: Nov 12, 2026 board to approve Q2 FY27 (unaudited) results
On schedule; result announcement imminent.
Summary: The customs duty is behind them; no other material regulatory risk flagged. West Africa capex is progressing (subsidiary share-capital increases in Sep confirm ongoing investment in Benin, Chad, Burkina Faso). Insider trading window closure suggests management confidence. Bulk deals in Aug (Microcurves Trading microcap rotation, not promoter-linked) were routine and non-material.
The narrative: Manorama Industries breached the ₹400 Cr quarterly mark in Q1 FY27 on the back of specialty-fats demand and strong operating execution. The customs duty outflow (₹20.64 Cr) was a one-quarter cash hit. Q2 is the proof: does revenue hold near ₹400 Cr, do margins stay 25%+, and will management reaffirm full-year guidance? The Street is constructive (₹2,003 median target, +25.9% upside), but the stock is pricing execution. A revenue beat or margin upside, paired with FY27 guide reaffirmation, re-rates the stock. A miss on either front (Q2 <₹370 Cr or margin <25%) risks 5–8% correction.
On result day (Nov 12): Focus on three things — (1) Q2 revenue & margin post-customs, (2) seasonality narrative (are we normalizing or demand-soft?), and (3) FY27 full-year guide (reaffirm, upgrade, or caution?). The fundamentals are sound; the debate is execution pace and consistency.
Informational and educational content only. Not investment advice.